Sihuan Pharmaceutical Holdings Group Ltd.
Industry Group: Pharmaceuticals
Country/Region: China
Identifier: HKG:460
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segments; and the generic medicine segment which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 418 out of 851
Universe
Global Universe 10225 out of 15104
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the non-India based rated subjects, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
| Company | ESG Risk Rating | Industry Rank |
|---|---|---|
| Sihuan Pharmaceutical Holdings Group Ltd. |
29.6
Medium
|
418 out of 851 |
| Tong Ren Tang Technologies Co., Ltd. |
32.5
High
|
540 out of 851 |
| Erasca, Inc. |
33.2
High
|
580 out of 851 |
| Sun Pharma Advanced Research Co. Ltd. |
41.2
Severe
|
826 out of 851 |
| Cronos Group, Inc. |
41.3
Severe
|
829 out of 851 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.